RxDoctor Payments Data

Joel Westrum

Optometrist · Stratford, IANPI 1801826334

Payments from drug & device makers

What this record shows

Alcon accounts for 81.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $1,217 and has fallen 85.8% since, to $173 in 2025. Among optometrist clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,202in general payments, 2019–2025

Across 83 payments — averaging $38.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • Johnson & Johnson Vision Care, Inc.$366
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$102
  • Dompe US, Inc.$22
  • Bausch & Lomb Americas Inc.$22
  • Optos, Inc.$20
  • plus $50 from 3 others

What the payments were for

  • Speaking & faculty fees$1,75055%
  • Food & beverage$1,45245%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,202 in reported general payments places this provider in the 90th percentile of 559 optometrist providers in Iowa.

See all optometrist providers in Iowa

Medicare billing

Part B allowed, 2024
$7,398
Medicare patients
43
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Latanoprost40$376
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha14$186

Paid to pharmacies, not to this prescriber.

Other optometrist in Stratford

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →